Sunitinib Plus Gemcitabine Active in Sarcomatoid, Poor-Risk Renal Cell Carcinoma

the ONA take:

Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for patients with aggressive renal cell carcinoma (RCC), a recent study published in the journal Cancer has shown.

Because no standard treatment exists for patients with sarcomatoid RCC, a type of kidney cancer associated with an aggressive biology and a poor prognosis, and treatment options for patients with poor-risk disease provide minimal benefit, researchers sought to evaluate the efficacy and safety of antiangiogenic therapy in combination with cytotoxic therapy in clinically aggressive RCC.

For the single-arm, phase 2 trial, researchers enrolled 39 patients with sarcomatoid RCC and 33 with poor-risk RCC. All patients received sunitinib plus gemcitabine.

Results showed that the objective response rate was 26% and 24% for patients with sarcomatoid RCC and poor-risk RCC, respectively.

The median time to progression was 5 months for patients with sarcomatoid RCC and 5.5 months for those with poor-risk RCC. Median overall survival was 10 months and 15 months, respectively.

In regard to safety, the most common grade 3 or higher treatment-associated adverse events were neutropenia, anemia, and fatigue.

“The combination may be more efficacious than either therapy alone and is currently under further investigation,” the authors conclude.

Sunitinib Plus Gemcitabine Active in Sarcomatoid, Poor-Risk Renal Cell Carcinoma
Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for aggressive renal cell carcinoma.
Michaelson, M. D., McKay, R. R., Werner, L., Atkins, M. B., Van Allen, E. M., Olivier, K. M., Song, J., Signoretti, S., McDermott, D. F. and Choueiri, T. K. (2015), Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer, 121: 3435-3443.
READ FULL ARTICLE From Wiley Online Library
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs